Recent Press Releases

5/21/2013 New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System
5/8/2013 Neuronetics is a Finalist for the 2013 Red Herring Top 100 North America Award
3/19/2013 NeuroStar TMS Therapy, a Non-Drug Depression Treatment, Demonstrates Statistically Significant Benefits on Patient-Reported Pain Outcomes
6/4/2012 Neuronetics, Inc. Receives CE Mark Approval for NeuroStar TMS Therapy
5/8/2012 Non-Drug Depression Treatment Rapidly and Significantly Improves Disease Symptoms and Quality of Life
3/12/2012 Neuronetics Announces NeuroStar TMS Therapy Will be Featured On The Dr. Oz Show
1/6/2012 Neuronetics Strengthens Commercialization Team with New Vice President of Marketing
10/17/2011 Neuronetics Appoints Vice President of Sales & Customer Service – Mark Saxton to Accelerate Growth of NeuroStar TMS Therapy
5/16/2011 Neuronetics, Inc. Raises $30 Million in Series E Financing – Polaris Venture Partners and Pfizer Lead the Round
5/14/2011 New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates with NeuroStar TMS Therapy in Patients with Major Depressive Disorder Treated in a Real World Practice Setting
5/8/2011 Neuronetics Wins TiE50 Award
4/14/2011 New Data Show No Negative Long-Term Effect in Cognitive Function in Patients with Major Depressive Disorder Treated with NeuroStar TMS Therapy®
3/2/2011 Neuronetics Appoints Vice President of Health Policy and Government Relations – Mary Hailey to Strengthen Reimbursement Team for NeuroStar TMS Therapy
1/10/2011 NeuroStar TMS Therapy Continues to Grow as a Standard of Care for Patients with Depression
9/1/2010 Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
5/17/2010 Data Continue to Demonstrate Value of NeuroStar TMS Therapy as a Proven Treatment for Patients Battling Difficult-to-Treat Depression
5/6/2010 Important TMS Therapy Study Results
2/18/2010 Neuronetics Advances Commercialization of New Depression Therapy; Hires Kim Tietz as Vice President, Marketing
11/12/2009 NeuroStar TMS Therapy® Receives Prestigious Popular Science Award
11/9/2009 Neuronetics Adds former CEO of VNUS Medical Technologies to Board of Directors
8/31/2009 Neuronetics, Inc. Raises $30 Million in Series D Financing
5/20/2009 Study Shows NeuroStar TMS Therapy® Improved Key Elements of Cognition in Patients with Major Depressive Disorder
4/20/2009 NeuroStar TMS Therapy Recipient of Medical Design Excellence Award
11/6/2008 New Study Demonstrates Cost Effectiveness of NeuroStar® TMS Therapy in the Treatment of Depression
10/8/2008 FDA Clears NeuroStar® TMS Therapy for the Treatment of Depression